Diazepam (Libervant) vs Lorazepam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Diazepam (Libervant)

Developed by Eton Pharmaceuticals, Inc. under a licence from Aquestive Therapeutics, Inc.

Phase 3 in Epilepsysmall molecule
Weak signal

NCT03428360 · Phase 3 · completed

The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.

Reported efficacy

Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) (Adverse events (AEs) were recorded from Day 1 through the last study contact (Month 7 telephone contact).); Number of Subjects in Safety Analysis Set With Adverse Events of Special Interest (AESI) (AESIs were recorded from Day 1 through the last study contact (Month 7 telephone contact).): Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) (Adverse events (AEs) were recorded from Day 1 through the last study contact (Month 7 telephone contact).): Safety Analysis Set: Enrolled Subjects With Epilepsy Who Received at Least 1 Dose of Study Drug — At least 1 TEAE: 84 Participants; At least 1 severe TEAE: 14 Participants; At least 1 study drug related TEAE: 10 Participants; At least 1 severe and related TEAE: 1 Participants; At least 1 serious TEAE: 18 Participants; At least 1 serious and related TEAE: 1 Participants (not_applicable)

Result source: NCT03428360

Lorazepam

Marketed by Hikma Pharmaceuticals PLC

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDiazepam (Libervant)Lorazepam
Seizure frequency, % change—Not reported—Not posted · NCT00004297
50% responder rate—Not reported—Not posted · NCT00004297
Seizure freedom—Not reported—Not posted · NCT00004297

Seizure frequency, % change

Diazepam (Libervant)
—Not reported
Lorazepam
—Not posted · NCT00004297

50% responder rate

Diazepam (Libervant)
—Not reported
Lorazepam
—Not posted · NCT00004297

Seizure freedom

Diazepam (Libervant)
—Not reported
Lorazepam
—Not posted · NCT00004297
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lorazepam: registry results are on file for Epilepsy, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Diazepam (Libervant): 2 of 4 rows · Lorazepam: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiazepam (Libervant)
Dropout rate
—Diazepam Buccal Film Following a H
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
show 1 more result
—Diazepam Buccal Film Following a M
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Discontinued due to AEs
—Diazepam Buccal Film Following a H
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
show 1 more result
—Diazepam Buccal Film Following a M
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Serious AEs
0%Diazepam Buccal Film Following a H
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
show 1 more result
0%Diazepam Buccal Film Following a M
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Most frequent reported AEs
sedation 10%
dizziness 0%
dysgeusia 0%
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
show 1 more result
somnolence 22.6%
dysgeusia 6.5%
fatigue 6.5%
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Libervant)'s landscape · Lorazepam's landscape